The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with ...

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) often needed to switch treatments on a regular basis as their therapies ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...